{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T12:23:08Z","timestamp":1786882988917,"version":"build-2736575974"},"reference-count":17,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2000,8,1]],"date-time":"2000-08-01T00:00:00Z","timestamp":965088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2000,8]]},"DOI":"10.1006\/rtph.2000.1402","type":"journal-article","created":{"date-parts":[[2002,9,18]],"date-time":"2002-09-18T17:19:16Z","timestamp":1032369556000},"page":"22-35","source":"Crossref","is-referenced-by-count":53,"title":["Human Safety and Pharmacokinetics of the CFC Alternative Propellants HFC 134a (1,1,1,2-Tetrafluoroethane) and HFC 227 (1,1,1,2,3,3,3-Heptafluoropropane) Following Whole-Body Exposure"],"prefix":"10.1006","volume":"32","author":[{"given":"H.H.","family":"Emmen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.G.","family":"Hoogendijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.A.A.","family":"Kl\u00f6pping-Ketelaars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Muijser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Duistermaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Ravensberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.J.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Borkhataria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.M.","family":"Rusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Schmit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1006\/rtph.2000.1402_RF1","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1177\/096032719501400902","article-title":"HFC 134a (1,1,1,2-tetrafluoroethane): Lack of oncogenicity in rodents after inhalation","volume":"14","author":"Alexander","year":"1995","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1006\/rtph.2000.1402_RF2","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1177\/096032719501400903","article-title":"An overview of the toxicology of HFC 134a","volume":"14","author":"Alexander","year":"1995","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1006\/rtph.2000.1402_RF3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/jam.1995.8.Suppl_1.S-29","article-title":"Safety of propellants","volume":"8","author":"Alexander","year":"1995","journal-title":"J. Aerosol. Med."},{"key":"10.1006\/rtph.2000.1402_RF4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0091-6749(98)70186-1","article-title":"Evaluation of a non-chlorofluorocarbon formulation of cromolyn sodium (Intal) metered-dose inhaler versus the chlorofluorocarbon formulation in the treatment of adult patients with asthma: a controlled trial","volume":"101","author":"Blumenthal","year":"1998","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1006\/rtph.2000.1402_RF5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1006\/faat.1995.1063","article-title":"1,1,1,2-Tetrafluoroethane: Repeat exposure inhalation toxicity in the rat, developmental toxicity in the rabbit, and genotoxicity in vitro and in vivo","volume":"25","author":"Collins","year":"1995","journal-title":"Fundam. Appl. Toxicol."},{"key":"10.1006\/rtph.2000.1402_RF6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/10408449991349203","article-title":"Rodent Leydig cell tumorigensis: A review of the physiology, pathology, mechanisms and relevance to humans","volume":"29","author":"Cook","year":"1999","journal-title":"Crit. Rev. Toxicol."},{"key":"10.1006\/rtph.2000.1402_RF7","first-page":"26","article-title":"CFC propellant substitution: P-134a as a potential replacement for P-12 in MDIs","author":"Dalby","year":"1990","journal-title":"Pharm. Technol."},{"key":"10.1006\/rtph.2000.1402_RF8","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3109\/00498259309166779","article-title":"Metabolic fate and deposition of 1,1,1,2-tetrafluoroethane (HFC 134a) in the rat following a single exposure by inhalation","volume":"23","author":"Ellis","year":"1993","journal-title":"Xenobiotica"},{"key":"10.1006\/rtph.2000.1402_RF9","series-title":"Joint Assessment of Commodity Chemicals No. 31, 1,1,1,2-Tetrafluoroethane (HFC-134a)","year":"1995"},{"key":"10.1006\/rtph.2000.1402_RF10","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.2042-7158.1996.tb05980.x","article-title":"Twenty-eight day double-blind safety study of an HFC 134a inhalation aerosol system in healthy subjects","volume":"48","author":"Harrison","year":"1996","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1006\/rtph.2000.1402_RF11","first-page":"663","article-title":"Tolerability and in vivo performance of a novel freon-free metered dose inhaler for a fixed combinational product of reproterol and disodium cromoglycate","volume":"48","author":"Hermann","year":"1998","journal-title":"Arzneimittelforschung"},{"key":"10.1006\/rtph.2000.1402_RF12","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/249810a0","article-title":"Stratospheric sink for chlorofluoromethanes: Chlorine atom catalyzed destruction of ozone","volume":"249","author":"Molina","year":"1974","journal-title":"Nature"},{"key":"10.1006\/rtph.2000.1402_RF13","first-page":"832","article-title":"Disposition of inhaled 1,1,1,2-tetrafluoroethane (HFA 134a) in healthy subjects and in patients with chronic airflow limitation","volume":"23","author":"Pike","year":"1995","journal-title":"Drug Metab. Dispos."},{"key":"10.1006\/rtph.2000.1402_RF14","series-title":"Toxicological Properties of Halon Substitutes","author":"Skaggs","year":"1995"},{"key":"10.1006\/rtph.2000.1402_RF15","series-title":"Environmental Effects of Ozone Depletion","year":"1991"},{"key":"10.1006\/rtph.2000.1402_RF16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/jam.1995.8.Suppl_1.S-35","article-title":"Clinical pharmacology of HFA 134a","volume":"8","author":"Ventresca","year":"1995","journal-title":"J. Aerosol Med."},{"key":"10.1006\/rtph.2000.1402_RF17","series-title":"Human Inhalation of Halon 1301, HFC 134a and HFC 227ea for Collection of Pharmacokinetic Data","author":"Vinegar","year":"1997"}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230000914028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230000914028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T20:27:07Z","timestamp":1557347227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230000914028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,8]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,8]]}},"alternative-id":["S0273230000914028"],"URL":"https:\/\/doi.org\/10.1006\/rtph.2000.1402","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2000,8]]}}}